Phosphoproteomics in cancer

Reversible protein phosphorylation serves as a basis for regulating a number of cellular processes. Aberrant activation of kinase signaling pathways is commonly associated with several cancers. Recent developments in phosphoprotein/phosphopeptide enrichment strategies and quantitative mass spectrometry have resulted in robust pipelines for high‐throughput characterization of phosphorylation in a global fashion. Today, it is possible to profile site‐specific phosphorylation events on thousands of proteins in a single experiment. The potential of this approach is already being realized to characterize signaling pathways that govern oncogenesis. In addition, chemical proteomic strategies have been used to unravel targets of kinase inhibitors, which are otherwise difficult to characterize. This review summarizes various approaches used for analysis of the phosphoproteome in general, and protein kinases in particular, highlighting key cancer phosphoproteomic studies.

[1]  P. Roepstorff,et al.  Highly Selective Enrichment of Phosphorylated Peptides from Peptide Mixtures Using Titanium Dioxide Microcolumns* , 2005, Molecular & Cellular Proteomics.

[2]  P. Roepstorff,et al.  Highly Efficient Phosphopeptide Enrichment by Calcium Phosphate Precipitation Combined with Subsequent IMAC Enrichment*S , 2007, Molecular & Cellular Proteomics.

[3]  Gil Mor,et al.  Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays , 2007, Proceedings of the National Academy of Sciences.

[4]  S. Kane,et al.  A Method to Identify Serine Kinase Substrates , 2002, The Journal of Biological Chemistry.

[5]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[6]  J. Porath,et al.  Isolation of phosphoproteins by immobilized metal (Fe3+) affinity chromatography. , 1986, Analytical biochemistry.

[7]  N. Hynes,et al.  ErbB receptors and signaling pathways in cancer. , 2009, Current opinion in cell biology.

[8]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[9]  J. Porath,et al.  Model studies on iron(III) ion affinity chromatography. II. Interaction of immobilized iron(III) ions with phosphorylated amino acids, peptides and proteins. , 1992, Journal of chromatography.

[10]  Tina N. Davis,et al.  Proteomic and genetic approaches identify Syk as an AML target. , 2009, Cancer cell.

[11]  R. Hruban,et al.  Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. , 2007, Journal of proteome research.

[12]  M. Mrksich,et al.  Peptide chips for the quantitative evaluation of protein kinase activity , 2002, Nature Biotechnology.

[13]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[14]  Akhilesh Pandey,et al.  Identification of c-Src Tyrosine Kinase Substrates Using Mass Spectrometry and Peptide Microarrays , 2008, Journal of proteome research.

[15]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[16]  B. Sefton.  The viral tyrosine protein kinases. , 1986, Current topics in microbiology and immunology.

[17]  Yin-kun Liu,et al.  Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells , 2009, BMC Cancer.

[18]  K. Parker,et al.  Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.

[19]  S. Honsawek,et al.  The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  S. Gygi,et al.  Profiling of UV-induced ATM/ATR signaling pathways , 2007, Proceedings of the National Academy of Sciences.

[21]  Tony Pawson,et al.  Cell-Specific Information Processing in Segregating Populations of Eph Receptor Ephrin–Expressing Cells , 2009, Science.

[22]  M. Mann,et al.  Global Effects of Kinase Inhibitors on Signaling Networks Revealed by Quantitative Phosphoproteomics , 2009, Molecular & Cellular Proteomics.

[23]  Matthias Mann,et al.  A Mass Spectrometry-based Proteomic Approach for Identification of Serine/Threonine-phosphorylated Proteins by Enrichment with Phospho-specific Antibodies , 2002, Molecular & Cellular Proteomics.

[24]  M. Cotten,et al.  An efficient proteomics method to identify the cellular targets of protein kinase inhibitors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Pandey,et al.  Global impact of oncogenic Src on a phosphotyrosine proteome. , 2008, Journal of proteome research.

[26]  K. Kinzler,et al.  Somatic mutations of EGFR in colorectal cancers and glioblastomas. , 2004, The New England journal of medicine.

[27]  L. Liotta,et al.  Quantitative cell signalling analysis reveals down‐regulation of MAPK pathway activation in colorectal cancer , 2009, The Journal of pathology.

[28]  Benjamin J Raphael,et al.  A New Approach for Quantitative Phosphoproteomic Dissection of Signaling Pathways Applied to T Cell Receptor Activation* , 2009, Molecular & Cellular Proteomics.

[29]  M. Posewitz,et al.  Immobilized gallium(III) affinity chromatography of phosphopeptides. , 1999, Analytical chemistry.

[30]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[31]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[32]  D. Ron,et al.  Characterization of phosphopeptides from protein digests using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and nanoelectrospray quadrupole time-of-flight mass spectrometry. , 2001, Rapid communications in mass spectrometry : RCM.

[33]  B. Chait,et al.  Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome , 2001, Nature Biotechnology.

[34]  T. Hunter.  Protein-Tryosine Kinases , 1985 .

[35]  C. Mummery,et al.  Phosphorylation dynamics during early differentiation of human embryonic stem cells. , 2009, Cell stem cell.

[36]  A. Levey,et al.  Phosphoproteomic analysis of human brain by calcium phosphate precipitation and mass spectrometry. , 2008, Journal of proteome research.

[37]  M. Posner,et al.  Generation of monoclonal antibodies against phosphotyrosine and their use for affinity purification of phosphotyrosine-containing proteins. , 1991, Methods in enzymology.

[38]  John R Yates,et al.  Cancer proteomics by quantitative shotgun proteomics , 2007, Molecular oncology.

[39]  Akhilesh Pandey,et al.  Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS , 2008, Proceedings of the National Academy of Sciences.

[40]  L. Brill,et al.  Phosphoproteomic analysis of human embryonic stem cells. , 2009, Cell stem cell.

[41]  T. Hunter,et al.  Protein-tyrosine kinases. , 1985, Annual review of biochemistry.

[42]  Ramars Amanchy,et al.  Phosphoproteome analysis of HeLa cells using stable isotope labeling with amino acids in cell culture (SILAC). , 2005, Journal of proteome research.

[43]  M. Mann,et al.  Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. , 2008, Journal of proteome research.

[44]  Tony Hunter,et al.  Evidence that the phosphorylation of tyrosine is essential for cellular transformation by Rous sarcoma virus , 1980, Cell.

[45]  D. Boschelli,et al.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.

[46]  J. Thomson,et al.  Human embryonic stem cell phosphoproteome revealed by electron transfer dissociation tandem mass spectrometry , 2009, Proceedings of the National Academy of Sciences.

[47]  J. Brugge,et al.  Identification of a transformation-specific antigen induced by an avian sarcoma virus , 1977, Nature.

[48]  Emanuel F Petricoin,et al.  Signal pathway profiling of ovarian cancer from human tissue specimens using reverse‐phase protein microarrays , 2003, Proteomics.

[49]  Cédric Leroy,et al.  Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. , 2009, Cancer research.

[50]  Y. Zong,et al.  The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R* , 2009, The Journal of Biological Chemistry.

[51]  Steven P Gygi,et al.  Signaling networks assembled by oncogenic EGFR and c-Met , 2008, Proceedings of the National Academy of Sciences.

[52]  Massimo Libra,et al.  Targeting prostate cancer based on signal transduction and cell cycle pathways , 2008, Cell cycle.

[53]  A. Heck,et al.  Selective isolation at the femtomole level of phosphopeptides from proteolytic digests using 2D-NanoLC-ESI-MS/MS and titanium oxide precolumns. , 2004, Analytical chemistry.

[54]  J. Griffiths,et al.  Multiple Reaction Monitoring to Identify Sites of Protein Phosphorylation with High Sensitivity *S , 2005, Molecular & Cellular Proteomics.

[55]  T. Yip,et al.  Mapping and sequence‐specific identification of phosphopeptides in unfractionated protein digest mixtures by matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry , 1992, FEBS letters.

[56]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[57]  M. Bemark,et al.  Identification of genes deregulated during serum‐free medium adaptation of a Burkitt's lymphoma cell line , 2008, Cell proliferation.

[58]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[59]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[60]  T. Hunter,et al.  Transforming gene product of Rous sarcoma virus phosphorylates tyrosine , 1980, Proceedings of the National Academy of Sciences.

[61]  W. Blackstock,et al.  Identification of Phosphorylation Sites on Neurofilament Proteins by Nanoelectrospray Mass Spectrometry* , 1997, The Journal of Biological Chemistry.

[62]  Akhilesh Pandey,et al.  Quantitative proteomics using stable isotope labeling with amino acids in cell culture , 2008, Nature Protocols.

[63]  M. Gerstein,et al.  Global analysis of protein phosphorylation in yeast , 2005, Nature.

[64]  J. Porath,et al.  Model studies on iron(III) ion affinity chromatography : Interaction of immobilized metal ions with nucleotides , 1991 .

[65]  G. Superti-Furga,et al.  Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells , 2009, Leukemia.

[66]  Hong Ma,et al.  Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways , 2002, Oncogene.

[67]  M. Mann,et al.  Dissection of the insulin signaling pathway via quantitative phosphoproteomics , 2008, Proceedings of the National Academy of Sciences.

[68]  Arthur R Salomon,et al.  Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry. , 2004, Analytical chemistry.

[69]  Sandra A. Moore,et al.  Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.

[70]  H. Varmus,et al.  Purification of DNA complementary to nucleotide sequences required for neoplastic transformation of fibroblasts by avian sarcoma viruses. , 1976, Journal of molecular biology.

[71]  P. Schultz,et al.  Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[72]  W. Talloen,et al.  Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout , 2009, Molecular Cancer Therapeutics.

[73]  D. Lauffenburger,et al.  Time-resolved Mass Spectrometry of Tyrosine Phosphorylation Sites in the Epidermal Growth Factor Receptor Signaling Network Reveals Dynamic Modules*S , 2005, Molecular & Cellular Proteomics.

[74]  G. Superti-Furga,et al.  A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells , 2010, Leukemia.

[75]  S. Gygi,et al.  Sensitive multiplexed analysis of kinase activities and activity-based kinase identification , 2009, Nature Biotechnology.

[76]  T. Hunter,et al.  Evidence that the Abelson virus protein functions in vivo as a protein kinase that phosphorylates tyrosine. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Gerhard Dürnberger,et al.  Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. , 2007, Blood.

[78]  M. Mann,et al.  Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. , 2009, Molecular cell.

[79]  C. Marshall,et al.  B-RAF is a therapeutic target in melanoma , 2004, Oncogene.

[80]  R. Österberg.  Metal and Hydrogen-Ion Binding Properties of O-Phosphoserine , 1957, Nature.

[81]  J Allison,et al.  An approach to locate phosphorylation sites in a phosphoprotein: mass mapping by combining specific enzymatic degradation with matrix-assisted laser desorption/ionization mass spectrometry. , 1994, Analytical biochemistry.

[82]  M. Mann,et al.  Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry. , 2010, Journal of proteome research.

[83]  Ramaswamy Nilakantan,et al.  Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase , 2004, Cancer Research.

[84]  Andrew D. Yates,et al.  A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer , 2005, Nature Genetics.

[85]  D. Arnott,et al.  Mass Spectrometric Contributions to the Practice of Phosphorylation Site Mapping through 2003 , 2005, Molecular & Cellular Proteomics.

[86]  D. Baltimore,et al.  Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine , 1980, Nature.

[87]  M. Kamps.  Generation and use of anti-phosphotyrosine antibodies for immunoblotting. , 1991, Methods in enzymology.

[88]  Florian Gnad,et al.  Large-scale Proteomics Analysis of the Human Kinome , 2009, Molecular & Cellular Proteomics.

[89]  Kimberly Lee,et al.  Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. , 2006, Leukemia research.

[90]  R. Aebersold,et al.  A systematic approach to the analysis of protein phosphorylation , 2001, Nature Biotechnology.

[91]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[92]  C. Braconi,et al.  Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. , 2008, Current cancer drug targets.

[93]  E. Anderson.  Hudson et al. , 1977 .

[94]  R. Cole,et al.  Identification of c‐Src tyrosine kinase substrates in platelet‐derived growth factor receptor signaling , 2009, Molecular oncology.

[95]  Suresh Mathivanan,et al.  Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry , 2007, Proceedings of the National Academy of Sciences.

[96]  A. Pandey,et al.  Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) for Studying Dynamics of Protein Abundance and Posttranslational Modifications , 2005, Science's STKE.

[97]  K. Resing,et al.  Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. , 2009, Molecular cell.

[98]  J. Rush,et al.  Immunoaffinity profiling of tyrosine phosphorylation in cancer cells , 2005, Nature Biotechnology.

[99]  J. Wang.  Antibodies for phosphotyrosine: analytical and preparative tool for tyrosyl-phosphorylated proteins. , 1988, Analytical biochemistry.

[100]  S. Kingsmore.  Multiplexed protein measurement: technologies and applications of protein and antibody arrays , 2006, Nature Reviews Drug Discovery.

[101]  A. Stensballe,et al.  Characterization of phosphoproteins from electrophoretic gels by nanoscale Fe(III) affinity chromatography with off‐line mass spectrometry analysis , 2001, Proteomics.

[102]  Romain M. Larive,et al.  Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell–cell adhesion , 2009, Oncogene.

[103]  H. Varmus,et al.  Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein , 1978, Cell.

[104]  S. Carr,et al.  Selective detection and sequencing of phosphopeptides at the femtomole level by mass spectrometry. , 1996, Analytical biochemistry.

[105]  Daniel B. McClatchy,et al.  Motif-specific sampling of phosphoproteomes. , 2008, Journal of proteome research.

[106]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[107]  Yiling Lu,et al.  Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma* , 2005, Molecular & Cellular Proteomics.

[108]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors , 2000 .

[109]  R. Annan,et al.  Hydrophilic Interaction Chromatography Reduces the Complexity of the Phosphoproteome and Improves Global Phosphopeptide Isolation and Detection*S , 2008, Molecular & Cellular Proteomics.

[110]  Young Yang,et al.  Serum starvation induces G1 arrest through suppression of Skp2-CDK2 and CDK4 in SK-OV-3 cells. , 2008, International journal of oncology.

[111]  H. Cooper,et al.  Differential Phosphoproteomics of Fibroblast Growth Factor Signaling: Identification of Src Family Kinase-Mediated Phosphorylation Events , 2010, Journal of proteome research.

[112]  Guoan Zhang,et al.  Use of stable isotope labeling by amino acids in cell culture (SILAC) for phosphotyrosine protein identification and quantitation. , 2009, Methods in molecular biology.

[113]  Kristen M. Naegle,et al.  An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells. , 2008, Molecular bioSystems.

[114]  Daniel S Spellman,et al.  Quantitative phosphotyrosine proteomics of EphB2 signaling by stable isotope labeling with amino acids in cell culture (SILAC). , 2006, Journal of proteome research.

[115]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[116]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[117]  Jos Joore,et al.  Kinome Profiling for Studying Lipopolysaccharide Signal Transduction in Human Peripheral Blood Mononuclear Cells* , 2004, Journal of Biological Chemistry.

[118]  F. Khuri,et al.  LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. , 2008, Cancer research.

[119]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[120]  K. Baggerly,et al.  Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines. , 2010, Journal of proteome research.

[121]  H. Varmus,et al.  Nucleotide sequences related to the transforming gene of avian sarcoma virus are present in DNA of uninfected vertebrates. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[122]  Paul Tempst,et al.  A Prototype Antibody Microarray Platform to Monitor Changes in Protein Tyrosine Phosphorylation* , 2004, Molecular & Cellular Proteomics.

[123]  Akira Sano,et al.  Titania as a Chemo-affinity Support for the Column-switching HPLC Analysis of Phosphopeptides: Application to the Characterization of Phosphorylation Sites in Proteins by Combination with Protease Digestion and Electrospray Ionization Mass Spectrometry , 2004, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[124]  D. Lauffenburger,et al.  Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks , 2007, Proceedings of the National Academy of Sciences.

[125]  B. A. Ballif,et al.  ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.

[126]  Z. Estrov,et al.  The JAK-STAT pathway: a therapeutic target in hematological malignancies. , 2006, Current cancer drug targets.

[127]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[128]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  M. Mann,et al.  Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. , 2008, Molecular cell.

[130]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[131]  Ron Bose,et al.  Phosphoproteomic analysis of Her2/neu signaling and inhibition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.